Know Cancer

or
forgot password

Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Untreated Advanced Non-Small Cell Lung Cancer

Thank you

Trial Information

Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)


Inclusion Criteria:



I am 18 years of age or older. I have advanced non-small lung cancer. I have not had any
major surgical procedures within 28 days prior to my starting treatment.

I have high blood pressure that is controlled. I am not on heparin, coumadin or lovonox
for treatment of medical conditions. I do not have serious wound healing problems. I have
not received any previous treatment, except radiation therapy for my disease.

Exclusion Criteria:

-

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

James Stevenson, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cooper University Hospital

Authority:

United States: Food and Drug Administration

Study ID:

AVF3158'S

NCT ID:

NCT00254319

Start Date:

Completion Date:

Related Keywords:

  • Untreated Advanced Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
The CINJ at Cooper University Hospital Voorhees, New Jersey  08043